Form 4: Q32 Bio Inc. Director Grayzel Reports Option Repricing and Grant

Director David S. Grayzel reports changes in beneficial ownership of Q32 Bio Inc. stock options, including repricing and new grants.

Summary

• David S. Grayzel, a director of Q32 Bio Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The report includes transactions related to stock options, specifically repricing of existing options and the grant of new options.
• On February 24, 2025, the Issuer's board of directors approved an option repricing.
• The exercise price of some options was adjusted to $2.54 per share, representing the fair market value on the repricing date.
• Grayzel also received new stock options on January 15, 2025, with an exercise price of $3.20.
• The options vest quarterly, contingent on continued service as a director.
• Some options were granted in lieu of cash retainer fees under the company's non-employee director compensation policy.
• The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC.

Sentiment

Score: 6

Explanation: The document is neutral, simply reporting transactions. The repricing could be seen as slightly positive, indicating an effort to incentivize the director, but it's not a strong signal.

Positives

• The repricing of options could incentivize the director to improve company performance.
• The grant of new options aligns the director's interests with those of shareholders.

Future Outlook

The options vest over time, contingent on continued service, suggesting an ongoing relationship between the director and the company.

Industry Context

Stock option grants and repricing are common practices in the biotech industry to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Option grants to directors are a standard component of compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their director compensation.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the option repricing and grants as a way to align director interests with company performance.
• The director is incentivized to contribute to the company's success to realize the value of the options.

Key Dates